Market Data 
Markets
Replies to post #41208 on SiNtx Technologies Inc (SINT)
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017
Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research
These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.
Rule 5815(d)(4)(A), entitled “Hearings Panel Monitor,” provides a Hearings Panel with
discretion to monitor a company for a period of up to one year after the date a company regains
compliance with a listing standard if it concludes that there is a likelihood that a company will
fail to maintain compliance with one or more listing standards during that period (including
requirements with which the company was not previously deficient). During this one-year
monitoring period, Staff will monitor the company, to confirm compliance with all listing
requirements. While Staff monitors all listed companies for compliance with the Exchange’s
listing standards, if Staff identifies a deficiency with any listing requirement for companies that
are being monitored under Rule 5815(d)(4)(A), staff may not provide the company with a cure or
compliance period, nor the opportunity to submit a plan to regain compliance with the
deficiency. Instead, Staff will issue a Delisting Determination for these companies.
Absolutely NO INVESTMENT FIRM, INSIDER or credible lending institution takes Sint for anything other than the joke that it is; hence it is left alone.
This contract will address material challenges in propulsion and guidance technology for next generation high-temperature Department of the Air Force systems.
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
AI
